Literature DB >> 4118636

Lithium therapy in Huntington's chorea and tardive dyskinesia.

P Dalén.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4118636     DOI: 10.1016/s0140-6736(73)90510-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

1.  Biochemical mechanisms and management of choreiform movement disorders.

Authors:  L de Silva
Journal:  Drugs       Date:  1977-10       Impact factor: 9.546

Review 2.  Orofacial dyskinesia. Clinical features, mechanisms and drug therapy.

Authors:  R M Kobayashi
Journal:  West J Med       Date:  1976-10

Review 3.  Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.

Authors:  Chi-Tso Chiu; De-Maw Chuang
Journal:  Pharmacol Ther       Date:  2010-08-10       Impact factor: 12.310

Review 4.  Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders.

Authors:  Sweta Shah; Marc Marie Dooms; Sofia Amaral-Garcia; Mariana Igoillo-Esteve
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

5.  Lithium does not interact with haloperidol in the dopaminergic pathways of the rat brain.

Authors:  A Reches; V Jackson-Lewis; S Fahn
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  Anti-depressant action of caesium chloride and its modification of chlorpromazine toxicity in mice.

Authors:  F S Messiha
Journal:  Br J Pharmacol       Date:  1978-09       Impact factor: 8.739

Review 7.  The behavioral actions of lithium in rodent models: leads to develop novel therapeutics.

Authors:  Kelley C O'Donnell; Todd D Gould
Journal:  Neurosci Biobehav Rev       Date:  2007-04-13       Impact factor: 8.989

Review 8.  Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward.

Authors:  Sara Melisa Arciniegas Ruiz; Hagit Eldar-Finkelman
Journal:  Front Mol Neurosci       Date:  2022-01-21       Impact factor: 5.639

Review 9.  Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?

Authors:  Lisa Scheuing; Chi-Tso Chiu; Hsiao-Mei Liao; Gabriel R Linares; De-Maw Chuang
Journal:  Int J Biol Sci       Date:  2014-09-10       Impact factor: 6.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.